Items tagged with Drug-resistant TB
Giorgia Sulis: Delamanid — a broken dream for patients with MDR-TB? (post with simple image)
When the new TB drug delamanid was approved by the European Medicines Agency (EMA) in 2013, it was one of only two new drugs approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in more than 40 years. Preliminary findings suggested that this new drug could have a promising role for treatment when used with an optimised background regimen (OBR)—results that led to the World Health Organization (WHO) conditionally endorsing the drug in 2014 and providing interim policy guidance.
WHO call for patient data on the treatment of drug-resistant TB (post with simple image)
Public call for individual patient data on treatment of multidrug- and rifampicin-resistant TB.
Indian civil society pushes for government use compulsory license on MDR-TB drugs (post with simple image)
Advocates appeal to the Prime Minister of India to issue a government use compulsory license for bedaquiline and delamanid to encourage generic competition.
New guide to shorter regimen for treating drug-resistant TB (post with simple image)
DR-TB STAT + TAG brief: Is Shorter Better? Understanding the Shorter Regimen For Treating Drug-Resistant Tuberculosis
WHO treatment guidelines for isoniazid-resistant TB (post with simple image)
The World Health Organization issues recommendations on management of isoniazid-resistant TB.
WHO response to STREAM Stage 1 preliminary results (post with simple image)
WHO issues a position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage 1 preliminary result.
Page 71 of 71 · Total posts: 0←First 70 71